KANTAR
25.8.2022 10:25:15 CEST | Business Wire | Press release
Kantar BrandZ’s Top 100 Chinese Brands 2022 has, for the second year in succession, surpassed the monumental $1 trillion mark, reaching $1.24 trillion in overall brand value, in what has been a uniquely challenging year for China, and the rest of the world.
Despite a decline of 20% year-on-year in the overall value of the Top 100 China ranking, Chinese businesses have demonstrated the importance of building and maintaining a resilient brand, particularly when faced with uncertainty and global challenges, such as retail and supply chain disruptions, inflation, rising energy costs and the resurgence of COVID-19 restrictions.
Tencent ($204.4bn) retained the number one spot for a second year running. The technology giant has been concentrating on its main business, expanding steadily and organically, and adhering to its technology innovation strategy. Tencent continues to explore the potential of new technologies in serving consumers, enabling industries and contributing to solving social challenges. At the same time, Alibaba (No.2, $137.0bn) continues to expand its portfolio of standalone retail offerings. Alcohol brand Moutai (No.3, $108.5bn) proved resilient as its brand value dipped only 2%, and continued its emergence as one China’s most popular premium brands.
The Kantar BrandZ Top 10 Most Valuable Chinese Brands 2022
Rank 2022 |
Brand |
Category |
Brand Value ($M USD) |
1 |
Tencent |
Media and Entertainment |
204,378 |
2 |
Alibaba |
Retail |
137,031 |
3 |
Moutai |
Alcohol |
108,490 |
4 |
Douyin |
Media and Entertainment |
43,483 |
5 |
Meituan |
Services Platform |
41,945 |
6 |
ICBC |
Banks |
36,017 |
7 |
JD |
Retail |
34,198 |
8 |
Huawei |
Consumer Technology |
33,663 |
9 |
Haier |
IoT Ecosystem |
33,206 |
10 |
Ping An |
Insurance |
26,320 |
Newcomers and fastest risers
Lifestyle-focused social platform Xiaohongshu (No.37, $6.6bn) meaning ‘Little Red Book’ and intelligent speech and AI technologies company iFLYTEK (No.53, $4.2bn) were the highest-ranking newcomers to join the China Top 100 this year, along with 13 others from nine categories, including five brands centred around food, drink, and casual dining, highlighting the potential brand value in these markets. Three brands re-entered the Chinese brand ranking this year: YTO (No.88, $2.0bn) , HAVAL (No.93, 1.8bn) and TCL (No.94, $1.8bn) .
Growing 66%, athletic apparel brand Li-Ning (No.64, $3.4bn) was the fastest-growing brand in the Top 100. It successfully combined technical innovations with nostalgic and patriotic styling cues while its cumulative investment in fashion has now paid off. Six brands: Li-Ning, China Telecom (No.28, $8.8bn), Chow Tai Fook (No.38, $6.1bn), Xing Hua Cun (No.52, $4.2bn), BYD (No.29, $8.7bn), and Haier (No.9, $33.2bn) - grew by more than 25%.
With a focus on collaboration, rather than competition, Haier (No.9, $33.2bn) has risen two places to break into the Top 10. Its global expansion strategy and constant innovation in both consumer and industrial technology applications has contributed to a year-on-year growth of 26% in brand value.
Car manufacturer BYD rose 29% in brand value due to rapid growth in both China and overseas markets and became the world’s best-selling new energy vehicle (NEV) brand during H1 2022, as Chinese car exports doubled passing two million units for the first time.
Building resilience
Historical Kantar BrandZ data shows that investing in strong brands not only insulates businesses from short term challenges, but also ensures a faster rebound relative to one’s competitors.
Commenting on the ability of Chinese brands to deal effectively with the many challenges faced by global businesses, Doreen Wang, Kantar Greater China CEO and Global Chair of Kantar BrandZ said: “In difficult economic times, having a strong brand does not make a business fully immune to changes of fortune, but it can help soften the blow. This year, we’ve studied the Kantar BrandZ data closely to gain insight into what gives brands their resilience and ability to steadily improve regardless of market conditions.”
She added: “During VUCA* times, Chinese brands can start with building stronger perceived value, embracing sustainability, and improving end-to-end innovation capability. Strong brands never shy away from uncertainties. Instead, they should take them head on with these actions to create higher brand value and ensure a better future.”
Smaller and stronger
This year was a year in which smaller Chinese brands gained ground on the larger, more established brands. Over the last six years, China’s 30 largest brands have come to represent a smaller proportion of the Top 100’s total value. This signals China’s emergence as a major brand landscape and as the ranking is rebalanced, China’s extensive showing of strong brands now features multiple category competitors, rather than a single dominant name.
Category picture remains stable
Media and Entertainment (26% share of total brand value) is once again the largest category in the Kantar BrandZ China Top 100, followed by Retail (16%) and Alcohol (12%). Taken together, these three categories account for just over half of the total value of the China Top 100 ranking.
Out of the 20 categories that were covered by both 2021 and 2022 China BrandZ rankings, five increased their total value year-on-year: Cars, Apparel, IoT Ecosystem, Energy and Telecom Providers.
The value of intelligent insights
Brands that continue to advertise intelligently, particularly during challenging times, tend to overperform compared to those that are inclined to cut back or suspend their brand-building activities. The rise of performance advertising led some Chinese brand managers to feel as if they had no choice but to prioritise short-term sales activations over long-term brand-building. However, it is possible to do both - provided that brands have the right data and insights at hand while navigating the dynamic world of Chinese e-commerce, which has grown to encompass new formats like live streaming, community group buying, and private-channel O2O storefronts. Successful brands must also continually strive to gain an accurate picture of their own strengths and weaknesses in consumers’ eyes.
Other key highlights from the analysis include:
- A rise in global exposure – 47 brands in the China Top 100 are building their value outside of China, which is an all-time high, up from just 40 brands in 2021. Consumer technology brand TCL (No.94, $1.8bn) has been planning and investing in top-level sports for years. TCL has signed endorsement contracts with FIBA, Copa América, and several international sports stars. Chinese brands’ global exposure is steadily improving over a period of time and overall, the Top 100 brands’ overseas operations contribute 8.8% to their business.
- Better at meta – China is well poised to take advantage of the emerging metaverse as research labs invest in 3D sound, haptic and body sensor technologies. Within the parameters of data protection and national regulations, there appear to be plenty of growth opportunities. Chinese consumers have already embraced innovations like virtual influencers and digital collectibles, as well as immersive online showrooms and experiences.
- Responsibility towards mental health – The stresses of the COVID-19 pandemic brought mental health to the forefront, especially in cities experiencing lockdowns. As digital brands work to safeguard users’ mental health as part of their larger responsibility toward social harmony, all brands should aim to incorporate mental well-being into their core value propositions as consumers look for emotional security in addition to functional performance.
- Holistic approach towards sustainability – Key measures of sustainability are now three times more important to a brand’s overall positive reputation than they were a decade ago. Consumer responses to advertisements carrying sustainability messages suggest that Chinese consumers have an innate desire to connect with the natural world. Chinese brands can help consumers worldwide to turn good intentions into even better actions. It all starts with cultural intelligence.
- A closer community – Chinese consumers have become prouder of, and more attached to, their local communities. During city-by-city lockdowns in 2020 and 2022, many urban residents came together to order groceries, care for the elderly, and support school-aged children. This provides continuing opportunities for brands operating in the areas of community group buying, and small-format neighbourhood stores, and has major implications for brands’ sustainability and purpose-driven initiatives.
The 2022 Kantar BrandZ Top 100 Most Valuable Chinese Brands ranking, report and extensive analysis are available now at www.kantar.com/campaigns/brandz/china
* VUCA stands for Volatility, Uncertainty, Complexity and Ambiguity
NOTES TO EDITORS
About Kantar BrandZ : Kantar BrandZ is the global currency when assessing brand value, quantifying the contribution of brands to business’ financial performance. Kantar’s annual global and local brand valuation rankings combine rigorously analysed financial data, with extensive brand equity research. Since 1998, BrandZ has shared brand-building insights with business leaders based on interviews with 4.1 million consumers, for 19,250 brands in 51 markets. Discover more about Kantar BrandZ here .
Grounded in consumer opinion, Kantar BrandZ analysis enables businesses to identify their brand’s strength in the market and provides clear strategic guidance on how to boost value for the long-term.
Kantar’s BrandZ Top 100 Most Valuable Chinese Brands is the most definitive and robust ranking of the country’s brands available, and the brands ranked must meet these eligibility criteria:
- The brand was originally created in Mainland China.
- The brand is owned by a publicly traded enterprise, or financials of the company owning the brand are audited by a major global accounting practice and published in the public domain.
- Chinese unicorn brands must have their most recent valuation publicly available
About Kantar: Kantar is the world’s leading marketing data and analytics company. We have a complete, unique and rounded understanding of how people think, feel and act; globally and locally in over 90 markets. By combining the deep expertise of our people, our data resources and benchmarks and our innovative analytics and technology, we help our clients understand people and inspire growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005516/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
